Table 1. Pharmacological and comorbidity data for all subjects at baseline (n=50).
| Prescribed drug |
Frequency in initial 50 volunteers (%) |
| Beta Blocker |
7 (14%) |
| Statin |
29 (58%) |
| ACE Inhibitor |
22 (44%) |
| Ca+ channel blocker |
10 (20%) |
| PPI |
11 (22%) |
| Diuretic |
12 (24%) |
| Inotrope |
4 (8%) |
| Biguinide |
11 (22%) |
| Anteplatelet therapy |
37 (74%) |
| Sulphonylureas |
5 (10%) |
| Insulin |
4 (8%) |
| Comorbidities/Previous interventions |
| Diabetes |
5 (10%) |
| Current coronary artery disease |
7 (14%) |
| Hypertension (controlled) |
22 (44%) |
| Previous PTCA (>12 months) |
1 (2%) |
| Previous CABG (>12 months) |
2 (4%) |
| Previous MI |
1 (2%) |
CABG - Coronary artery bypass graftPTCA - Percutaneous transluminal coronary angioplasty
